84 related articles for article (PubMed ID: 6459234)
1. Use of an antiosteolytic agent in treatment of patients with bone metastases from breast cancer.
Dady PJ; Coombes RC; Smith IE; Parsons CA; Ford HT; Gazet JC; Henk JM; Nash AG; Powles TJ
Eur J Cancer (1965); 1980; Suppl 1():131-5. PubMed ID: 6459234
[No Abstract] [Full Text] [Related]
2. Effect of mithramycin on widespread painful bone metastases in cancer of the breast.
Davies J; Trask C; Souhami RL
Cancer Treat Rep; 1979; 63(11-12):1835-8. PubMed ID: 93511
[TBL] [Abstract][Full Text] [Related]
3. [Double-blind trial of oral clodronate in breast cancer patients with bone metastases].
Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
Bull Cancer; 1993; 80(10 Suppl):50-6. PubMed ID: 8081032
[No Abstract] [Full Text] [Related]
4. [Use of adriablastine in the combined chemotherapy of breast cancer patients with bone metastases].
Korman DB; Borisov AI; Maslova IA; Dobroskok LB
Vopr Onkol; 1980; 26(8):20-4. PubMed ID: 7415044
[TBL] [Abstract][Full Text] [Related]
5. The treatment of hypercalcemia associated with metastases to bone from primary breast cancer.
Ariel IM; Kempner R
Bull Hosp Jt Dis Orthop Inst; 1988; 48(1):82-7. PubMed ID: 2840153
[TBL] [Abstract][Full Text] [Related]
6. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
7. [Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].
Polico C; Nascimben O; Maccari F; Fazzin G
Quad Sclavo Diagn; 1978 Dec; 14(4):486-93. PubMed ID: 757622
[TBL] [Abstract][Full Text] [Related]
8. [Hydroxyprolinuria in relation to bone metastases in patients with breast cancer].
Rico Lenza H; Millán Núñez-Cortés J; Rodríguez Mora VI; Espinós Pérez D
Rev Esp Oncol; 1980; 27(1):61-6. PubMed ID: 7209108
[TBL] [Abstract][Full Text] [Related]
9. Calcium metabolism in breast cancer.
Coombes RC; Powles TJ; Joplin DG
Proc R Soc Med; 1977 Mar; 70(3):195-9. PubMed ID: 870901
[TBL] [Abstract][Full Text] [Related]
10. [Bisphosphonates in anti-osteolytic therapy of metastasizing breast carcinoma].
Diel IJ; Solomayer EF
Zentralbl Gynakol; 1996; 118(10):582-6. PubMed ID: 8999719
[TBL] [Abstract][Full Text] [Related]
11. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
Vinholes J; Coleman R; Lacombe D; Rose C; Tubiana-Hulin M; Bastit P; Wildiers J; Michel J; Leonard R; Nortier J; Mignolet F; Ford J
Br J Cancer; 1999 Apr; 80(1-2):221-8. PubMed ID: 10390000
[TBL] [Abstract][Full Text] [Related]
12. [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
Abe O; Izuo M; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
Gan To Kagaku Ryoho; 1982 May; 9(5):866-73. PubMed ID: 7184431
[TBL] [Abstract][Full Text] [Related]
13. Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases.
Mihai R; Stevens J; McKinney C; Ibrahim NB
Eur J Surg Oncol; 2006 Jun; 32(5):511-5. PubMed ID: 16564154
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyproline and zinc excretion in patients with neoplastic breast disease.
Percudani M; Dell'Anna B; De Lorenzis GF; Ferraccioli GF; Vaona GL
Int Surg; 1981; 66(3):233-6. PubMed ID: 7319736
[TBL] [Abstract][Full Text] [Related]
15. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
[TBL] [Abstract][Full Text] [Related]
16. [Encouraging results with cytostatic therapy in metastasizing breast cancer (author's transl)].
Michlmayr G; Kratzer H; Denz H; Huber H
Wien Klin Wochenschr; 1981 Mar; 93(6):205-7. PubMed ID: 7281697
[TBL] [Abstract][Full Text] [Related]
17. Increased Dickkopf-1 expression in breast cancer bone metastases.
Voorzanger-Rousselot N; Goehrig D; Journe F; Doriath V; Body JJ; Clézardin P; Garnero P
Br J Cancer; 2007 Oct; 97(7):964-70. PubMed ID: 17876334
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
19. Hypercalcemia in patients with advanced mammary cancer and osseous metastases. Effect of hormone therapy and schedule of treatment.
Donovan AJ; Bethune JE; Berne TV
Am Surg; 1966 Oct; 32(10):673-80. PubMed ID: 5921429
[No Abstract] [Full Text] [Related]
20. Feasibility and therapeutic efficacy of weekly 1-h low-dose paclitaxel infusion for relapsed breast cancer.
Kim R; Osaki A; Toge T
Oncol Rep; 2003; 10(1):145-50. PubMed ID: 12469161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
